AAPS Arden Conference

March 9-11, 2020
Sheraton Imperial Hotel
Raleigh-Durham Airport at Research Triangle Park

Call for Papers

- The Contributed Paper Abstract submission site for poster presentation, opens October 11, 2019.
- Email your poster abstract in a Word (.doc) file to abstracts@aaps.org
- 40 Poster slots available. (First to submit and register to attend will fill the slots)
- The submission deadline is January 13, 2020* at 5:00pm Eastern time. (*Date may change if all 40 slots are confirmed earlier than this date.)

IMPORTANT DATES

Poster Abstract Submission Timeline

Submission Deadline	*January 13, 2020
Registration Deadline for Presenting Authors	*January 13, 2020
Notification (Accept or Reject)	sent as received/registered
Schedule Notification Sent	January 20, 2020

SUBMISSION REQUIREMENTS

1. **Conditions and Policies**
   Persons submitting an abstract for presentation at the AAPS workshop are doing so with the understanding that they agree to abide by the conditions and policies provided below, as well as the decisions of the Screening Committee and AAPS staff. Questions should be directed to abstracts@aaps.org.

2. **Registration Requirement for Publication**
   The presenting author is required to attend the meeting to present the paper. If the presenting author is unable to attend the meeting, the co-author is responsible for the presentation. Registration is required for the author that will be presenting the paper at the meeting.

3. **Cancellation policy**
   If the author that will be presenting the paper cancels his/her registration between the dates of January 13, 2020 and February 13, 2020, AAPS will impose a $100 administrative fee. After February 13, 2020 no refunds will be issued. Registrant substitutions from the same company are allowed and may be submitted in writing at any time without penalty. If the

membership status of the substitute differs from that of the original registrant, a refund or additional charge may apply.

4. **Ethics Statement**
   Final poster presentations must include the accepted abstract and should include all methods used and data resulting from the research. Actions such as omission of data from a poster presentation that was included in the submitted abstract will be considered unethical. Authors and organizations violating these requirements will be subject to penalties such as restrictions from presenting future posters.

POSTER ABSTRACT POLICIES AND PROCEDURES

Permissions/Clearances
It is the responsibility of the author(s) to obtain the necessary permissions and clearances for all research prior to submission of the abstract. AAPS assumes no liability or responsibility for the publication of any material that is submitted.

Acceptance Criteria
Acceptance of the abstract for presentation will be based on the concise, accurate presentation of new data that is relevant to the field of pharmaceutical research. It is imperative that data is presented in the results section so that AAPS screeners can judge the scientific value of your abstract. Include all research information, data, charts and graphs in your submission so that it can be reviewed in its entirety.

Rejection Criteria
Criteria for rejection include:

- lack of data,
- stating data will be included in the poster presentation,
- commerciality,
- inconsistent or ambiguous data,
- reviews of literature,
- lack of novelty or innovation,
- plagiarism
- previously published, but not acknowledged, or
- failure to follow format guidelines (Purpose, Methods, Results, and Conclusion).

Abstract Revisions
Revisions can be made at any time before the January 13, 2020, submission deadline. ***Revisions cannot be made after the submission deadline***. Proofread, spell check and verify that all authors are listed on your abstract before submitting—the abstracts will be printed exactly as they appear when submitted.

Notification of Receipt and Verification of Submission
You will receive a confirmation email once your abstract is received. This notification only confirms receipt of your submission and is not a notification of acceptance.

Screening/Presentation
Final assignment to poster sessions will be made at the discretion of the screening committee.

Notification of Acceptance
Status notifications will be sent via email once registration is complete for the presenting author. Notification and updates will be sent to the *submitting author* only.

Notification of Presentation Schedule and Poster Number
Notifications will be sent via email by **January 20, 2020,** with the presentation date, time and poster number for the abstract. If you do not receive notification at that time, please contact AAPS at abstracts@aaps.org for an update on the schedule of your abstract. Scheduling notifications will be sent to the submitting author.

Abstract Withdrawal
To withdraw your abstract, a written request must be sent to abstracts@aaps.org**.** This request should be sent by the submitting author and must include the abstract title and abstract submission ID number. AAPS will acknowledge all withdrawal notifications by email.

Copyright/Permissions

- By submitting this poster abstract to AAPS, I state that all authors listed thereon are aware that they are listed.
- By submitting this poster abstract to AAPS, I give AAPS permission to display and publish the abstract in various ways related to the conference.

Poster Abstract Submission Format

Sample Abstract – Last page of this document

1. Word (doc) document
2. Title of Abstract (this will be your poster title), Times Roman 12, Bold
3. Author(s), Affiliation(s), Times Roman 10
4. Section Headings: Purpose, Methods, Results, Conclusion, Arial 10
5. Reference(s) (if needed) – Arial 10
6. Acknowledgement(s) (if needed) – Arial 10

Poster Abstract Submissions—Topics

- Analysis and Pharmaceutical Quality
- Biosimilars
- Biotechnology
- Chemistry, Manufacturing, and Controls (CMC)
- Formulation Design and Development
- Manufacturing Science and Engineering
- Patient-Centric Drug Development, Product Design, and Manufacturing
- Preformulation
- Process Development
- Protein Aggregation and Biological Consequences
- Protein Purification, Storage, and Transportation
- QbD and Product Performance
- Regulatory Sciences
- Stability
- Sterile Products

Submitting Your Poster Abstract

1. Email to abstracts@aaps.org
2. Subject of Email: Arden 2020 (or name of event)
3. Attach Word (doc) file to email
4. Body of Email - Indicate the Topic the abstract relates to.
5. Include contact information for the submitter of the abstract
    a. Last Name, First Name, Middle Initial
    b. Company/Affiliation Name
    c. Email Address
    d. Phone Number
6. Indicate the Presenting Author of the Poster
    a. Last Name, First Name, Middle Initial
    b. Company/Affiliation Name
    c. Email Address
    d. Phone Number

Sample Abstract

Quantitative Determination of Compound X in Rat and Dog Plasma using LC/MS/MS

Doe, J, AAPS; Smith, J, Blank Corp.

Purpose: To develop and validate an LC/MS/MS method for the determination of compound X, an anti-cancer agent in rat and dog plasma.

Methods: This method utilized a solid phase extraction from 0.1 mL plasma with an Isolute C2 cartridge and methanol as eluent. HPLC separation was carried out on a Phenomenex Luna C18 column (150 x 4.6 mm) column at a flow rate of 0.3 mL/min with an analysis time of 4.5 minutes. Compounds were eluted using a mobile phase of H20/CH3CN/HCOOH: 70/30/0.1 (v/v/v), pH 4.0. Compound Y, a structural analogue of compound X was used as the internal standard to account for differences due to adsorption, extraction, and instrumental performance. Mass spectrometry detection was carried out with a PE Sciex API III+ triple quadrupole mass spectrometer equipped with a Turbo IonSpray as LC/MS interface. ESI mass spectra were acquired in positive ion mode with multiple reaction monitoring.

Results: No matrix interference was observed across the elution windows of X and Y, indicating the specificity of the method. Acceptable intraday and interday assay precision (<5% CV) and accuracy (<10% diff.) were observed over a linear range of 1-1500 nM for both matrices. The mean (n=3) correlation coefficients in rat and dog plasma were 0.9998_0.0001 and 0.9997_0.0002, respectively. The mean extraction recovery was 91.2_2.5% and 90.1_4.6% for rat and dog plasma, respectively.

Conclusion: A validated method which was robust, sensitive, specific, accurate, and reliable was developed. The method has been used to quantify rat and dog plasma for pharmacokinetic and drug safety studies.